Skip to main content
Fig. 3 | Cell Communication and Signaling

Fig. 3

From: Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer

Fig. 3

Therapeutic strategies based on clinical and vitro studies. Erlotinib combined with osimertinib, or gefitinib combined with osimertinib both have certain effects on the EGFR C797S/T790M trans configuration based on vitro studies and clinical evidence. Brigatinib combined with cetuximab or CH7233163 or BLU-945 treatment exhibited potent anti-tumor activity against the EGFR ex19del /T790M/C797S triple mutation. Brigatinib combined with bevacizumab and osimertinib or EAI045 or BLU-945 combined with cetuximab treatment, have a significant effect on the EGFR L858R-T790M-C797S triple mutation. Afatinib treatment is a potentially effective strategy for EGFR L858R/L718Q/V or EGFR G719S/C or EGFR ex19del/G724S mutation based on clinical cases or research evidence. Gefitinib can combat lung adenocarcinoma with EGFR L858R-cis T790M-L792H triple mutation in vitro

Back to article page

Cell Communication and Signaling

ISSN: 1478-811X